Back to search results

Active Surveillance for Low-Risk Basal Cell Carcinoma in Elderly Patients

This study is looking at whether "active surveillance" (AS) is a good option for older patients with low-risk basal cell carcinoma (LR-BCC), a common and slow-growing skin cancer that rarely spreads. AS means carefully watching the cancer instead of treating it right away. The study wants to see if patients are as satisfied with AS as they are with standard treatments. You might be able to join if you are 65 or older, a patient at the University of Michigan Department of Dermatology, and have a recent diagnosis of LR-BCC. The study will measure how many people choose to enroll in the main part of the study and how satisfied patients are with their care after one year.

Study design
This is an interventional study planning to enroll 81 participants. It will compare active surveillance with standard of care treatment.
What's involved
Participants will either receive standard of care treatment or undergo active surveillance, which includes watching an educational video. They will also complete surveys.
Compensation
Not stated in the trial record.
Follow-up
Patient satisfaction will be measured at 52 weeks (about one year) after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06539468

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Active, Not Recruiting
NAAges 65+InterventionalTreatment
University of Michigan Rogel Cancer Center
~81 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Best PracticeEducational ActivityPatient ObservationSurvey Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment in part B (Part A)
Measured over 6 months
+1 more outcome measured

Conditions

Skin Basal Cell Carcinoma

Explore related trials

Basal Cell Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Allison Billi · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject of any gender aged ≥ 65 years at the time of enrollment
Patient at University of Michigan Department of Dermatology (UMichDD)
Willing and able to provide informed consent
Willing and able to comply with the protocol requirements
Histopathologic diagnosis of one or more LR-BCC(s) within 2 months of enrollment. LR-BCC is defined here as biopsy proven primary (not recurrent) BCC of any morphologic subtype; \< 2cm in size; with or without marginal involvement on histopathology; and located on the trunk or extremities excluding pretibial surface, hands, feet, nail units, and ankles (corresponding to area L in the Mohs Appropriate Use Criteria, representing the lowest risk areas)

Exclusion

Individuals who are immunocompromised per judgement of investigator (examples include but are not limited to patients on immunosuppressive medications such as prednisone \> 10 mg daily, uncontrolled HIV, and organ transplant recipients on immunosuppressive therapy)
Individuals who expect to relocate and will be unable to return to UMichDD for clinical follow-up visit(s)
Individuals with a genetic syndrome predisposing to development of basal cell carcinoma

What this trial measures

  • Enrollment in part B (Part A)6 months

    Will evaluate the associations between baseline characteristics and the primary outcome of enrollment in part B (up to accrual target for 100 subjects) by logistic regression. Baseline characteristics include demographics, clinical data, patient-reported measures, baseline comfort with active surveillance (AS), and interest in enrollment in part B. The clinical research coordinator will assign each participant in part A a value of 1 if enrolled in part B or 0 if not enrolled (up to accrual target of 100 subjects for part B).

  • Satisfaction with AS/standard of care (SOC) (Part B)At week 52

    Will compare the satisfaction of participants randomized to AS versus SOC as measured by five-point Likert scale.